|
|
|
|
30.06.25 - 13:33
|
Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Primary Membranous Nephropathy (GlobeNewswire EN)
|
|
CAMBRIDGE, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced the initiation of dosing in the global clinical study, PROMINENT. The Phase 3 study will evaluate the efficacy and safety of the investigational drug felzartamab compared to tacrolimus in adults diagnosed with primary membranous nephropathy (PMN). PROMINENT is designed to enroll approximately 180 adults with PMN and expected to readout in 2029. PMN is a severe antibody-mediated disease of the kidney that is a leading cause of nephrotic syndrome and carries a significant risk of kidney failure....
|
|
|
27.06.25 - 16:03
|
New Data for Nusinersen Underscore Biogen′s Commitment to Advancing Clinical Research to Improve Outcomes in SMA (GlobeNewswire EN)
|
|
CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen's applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months....
|
|
|
25.06.25 - 13:33
|
Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results (GlobeNewswire EN)
|
|
CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced topline results from the Phase 1 study of salanersen (BIIB115/ION306), an antisense oligonucleotide (ASO) being developed for the treatment of spinal muscular atrophy (SMA). Leveraging the same mechanism of action as SPINRAZA (nusinersen) but designed to achieve greater potency, salanersen has the potential to achieve high efficacy and enable once yearly dosing. An interim analysis of the Phase 1 study in participants with SMA who were previously treated with gene therapy was conducted to inform the decision on whether to move salanersen forward into registrational studies. Both dose levels tested, 40 mg and 80 mg, given once a year, were generally well-tolerated and led to substantial slowing of neurodegeneration, as shown by reductions in neurofilament. Exploratory clinical outcome data shows clinically meaningful improvements in function and attainment of new World Health Organization (WHO) milestones over 1 yea...
|
|
|
|
12.06.25 - 21:33
|
Demystifying Biogen: Insights From 11 Analyst Reviews (Benzinga)
|
|
Latest Ratings for BIIB
DateFirmActionFromTo Mar 2022StifelDowngradesBuyHold Mar 2022RBC CapitalUpgradesSector PerformOutperform Feb 2022Canaccord GenuityMaintainsBuy
View More Analyst Ratings for BIIB
View the Latest Analyst Ratings
read more...
|
|
|
|
|
12.06.25 - 07:03
|
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity (GlobeNewswire EN)
|
|
BRUSSELS and CAMBRIDGE, Mass., June 12, 2025 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented additional detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate. In the study, DZP demonstrated significant clinical improvements in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE), as measured by the British Isles Lupus Assessment Group (BILAG)-based Composite Lupus Assessment (BICLA) at Week 48, the primary endpoint. Improvements were also seen across additional clinical measures, including fatigue and disease activity/remission. These results were presented at EULAR 2025, the European Alliance of Associations for Rheumatology's annual meeting, in Barcelona, Spain. The safety and efficacy of DZP in SLE have not been established, and it is not approved for use in SLE by any regulatory authority worldwide. A second Phase 3 trial of dapirolizu...
|
|
|
|
|
|
22.05.25 - 08:51
|
Aufschlag von 246 Prozent! Sanofi greift nach Alzheimer-Hoffnung (Der Aktionaer)
|
|
Trotz der Verfügbarkeit des Alzheimer-Medikaments Leqembi (Lecanemab) vom Forschungsduo Eisai respektive Biogen ist der Bedarf an Therapien zur Behandlung der Demenzform weiterhin extrem hoch. Sanofi will sich nun einen Hoffnungsträger gegen Alzheimer unter den Nagel reißen, der sich in der klinischen Entwicklungsphase befindet....
|
|